The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors

NCT03507543 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumours
Breast Cancer
Ovarian Cancer
Prostate Cancer
Primary Peritoneal Cancer

Interventions

DRUG: IMP4297

Sponsor

Impact Therapeutics, Inc.